Skip to main content
Top

23-04-2024 | Hepatic Encephalopathy | Original Article

A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates

Authors: Patrick A. Twohig, Thoetchai Bee Peeraphatdit, Kaeli Samson, Makayla Schissel, Lynette Smith, Allison Ashford, Laura Freese, Timothy McCashland

Published in: Digestive Diseases and Sciences

Login to get access

Abstract

Background

Over 50% of hospitalizations from hepatic encephalopathy (HE) are preventable, but patients often do not receive medical treatment.

Aims

To use a multimodal education intervention (MMEI) to increase HE treatment rates and to evaluate (1) trends in HE treatment, (2) predictors of receiving treatment, and (3) the impact of treatment on hospitalization outcomes.

Methods

Prospective single-center cohort study of patients hospitalized with HE from April 1, 2020–September 30, 2022. The first 15 months were a control (“pre-MMEI”), the subsequent 15 months (MMEI) included three phases: (1) prior authorization resources, (2) electronic order set, and (3) in-person provider education. Treatment included receiving any drug (lactulose or rifaximin), or combination therapy. Treatment rates pre- vs. post-MMEI were compared using logistic regression.

Results

471 patients were included. There were lower odds of receiving any drug post-MMEI (p = 0.03). There was no difference in receiving combination therapy pre- or post-MMEI (p = 0.32). Predictors of receiving any drug included alcohol-related or cryptogenic cirrhosis (p’s < 0.001), and the presence of ascites (p = 0.005) and/or portal hypertension (p = 0.003). The only significant predictor of not receiving any drug treatment was having autoimmune cirrhosis (p < 0.001). Patients seen by internal medicine (p = 0.01) or who were intoxicated (p = 0.02) were less likely to receive rifaximin. Any treatment was associated with higher 30-day liver disease-specific readmission (p < 0.001).

Conclusion

This MMEI did not increase HE treatment rates, suggesting that alternative strategies are needed to identify and address barriers to treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–721.PubMedCrossRef Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–721.PubMedCrossRef
2.
go back to reference Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–735.PubMedCrossRef Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–735.PubMedCrossRef
3.
go back to reference American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease. practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;2014:642–659. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease. practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;2014:642–659.
4.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol 2022;77:807–824.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol 2022;77:807–824.CrossRef
5.
go back to reference Bajaj JS, O’Leary JG, Tandon P et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol 2017;15:565–574.PubMedCrossRef Bajaj JS, O’Leary JG, Tandon P et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol 2017;15:565–574.PubMedCrossRef
6.
go back to reference Patidar KR, Thacker LR, Wade JB et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014;109:1757.PubMedPubMedCentralCrossRef Patidar KR, Thacker LR, Wade JB et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014;109:1757.PubMedPubMedCentralCrossRef
7.
go back to reference Tapper EB, Aberasturi D, Zhao Z et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020;51:1397–1405.PubMedPubMedCentralCrossRef Tapper EB, Aberasturi D, Zhao Z et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020;51:1397–1405.PubMedPubMedCentralCrossRef
8.
go back to reference Moon AM, Kim HP, Jiang Y et al. Systematic review and meta-analysis on the effects of lactulose and Rifaximin on patient-reported outcomes in hepatic encephalopathy. Am J Gastroenterol. 2023;118:284–293.PubMedCrossRef Moon AM, Kim HP, Jiang Y et al. Systematic review and meta-analysis on the effects of lactulose and Rifaximin on patient-reported outcomes in hepatic encephalopathy. Am J Gastroenterol. 2023;118:284–293.PubMedCrossRef
9.
go back to reference Bajaj JS, Saeian K, Schubert CM et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175–1183.PubMedCrossRef Bajaj JS, Saeian K, Schubert CM et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175–1183.PubMedCrossRef
10.
go back to reference Gluud LL, Jeyaraj R, Morgan MY. Outcomes in clinical trials evaluating interventions for the prevention and treatment of hepatic encephalopathy. J Clin Exp Hepatol 2019;9:354–361.PubMedPubMedCentralCrossRef Gluud LL, Jeyaraj R, Morgan MY. Outcomes in clinical trials evaluating interventions for the prevention and treatment of hepatic encephalopathy. J Clin Exp Hepatol 2019;9:354–361.PubMedPubMedCentralCrossRef
11.
go back to reference Tapper EB, Henderson JB, Parikh ND et al. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans With cirrhosis. Hepatol Commun. 2019;3:1510–1519.PubMedPubMedCentralCrossRef Tapper EB, Henderson JB, Parikh ND et al. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans With cirrhosis. Hepatol Commun. 2019;3:1510–1519.PubMedPubMedCentralCrossRef
12.
go back to reference D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–231.PubMedCrossRef D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–231.PubMedCrossRef
13.
go back to reference Bajaj JS, Lauridsen M, Tapper EB et al. Important unresolved questions in the management of hepatic encephalopathy: An ISHEN consensus. Am J Gastroenterol 2020;115:989–1002.PubMedCrossRef Bajaj JS, Lauridsen M, Tapper EB et al. Important unresolved questions in the management of hepatic encephalopathy: An ISHEN consensus. Am J Gastroenterol 2020;115:989–1002.PubMedCrossRef
14.
go back to reference Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164–1171.PubMedCrossRef Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164–1171.PubMedCrossRef
15.
go back to reference Bajaj JS, Sanyal AJ, Bell D et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010;31:1012–1017.PubMedCrossRef Bajaj JS, Sanyal AJ, Bell D et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010;31:1012–1017.PubMedCrossRef
16.
go back to reference Zeng Z, Li YY, Jia L et al. Influence of lactulose on the cognitive level and quality of life in patients with minimal hepatic encephalopathy. Chin J Clin Rehabil 2006;10:165–167. Zeng Z, Li YY, Jia L et al. Influence of lactulose on the cognitive level and quality of life in patients with minimal hepatic encephalopathy. Chin J Clin Rehabil 2006;10:165–167.
17.
go back to reference Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–1081.PubMedCrossRef Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–1081.PubMedCrossRef
18.
go back to reference Ali B, Zaidi YA, Alam A, Anjum HA. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak 2014;24:269–273.PubMed Ali B, Zaidi YA, Alam A, Anjum HA. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak 2014;24:269–273.PubMed
19.
go back to reference Kimer A, Krag A, Møller S et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.PubMedCrossRef Kimer A, Krag A, Møller S et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.PubMedCrossRef
20.
go back to reference Sanyal A, Younossi ZM, Bass NM et al. Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy—a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:853–861.PubMedCrossRef Sanyal A, Younossi ZM, Bass NM et al. Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy—a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:853–861.PubMedCrossRef
21.
go back to reference Sidhu SS, Goyal O, Parker RA et al. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int 2016;36:378–85.PubMedCrossRef Sidhu SS, Goyal O, Parker RA et al. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int 2016;36:378–85.PubMedCrossRef
22.
go back to reference Kimer N, Krag A, Moller S et al. Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.PubMedCrossRef Kimer N, Krag A, Moller S et al. Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.PubMedCrossRef
23.
go back to reference Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016;43:11–26.PubMedCrossRef Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016;43:11–26.PubMedCrossRef
24.
go back to reference Prasad S, Dhiman RK, Duseja A et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–559.PubMedCrossRef Prasad S, Dhiman RK, Duseja A et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–559.PubMedCrossRef
25.
go back to reference Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol. 2011;4:199–206.CrossRef Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol. 2011;4:199–206.CrossRef
26.
go back to reference Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol 2019;31:434–450.PubMedCrossRef Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol 2019;31:434–450.PubMedCrossRef
27.
go back to reference Dhiman RK, Thumburu KK, Verma N et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2020;18:800–812.PubMedCrossRef Dhiman RK, Thumburu KK, Verma N et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2020;18:800–812.PubMedCrossRef
28.
go back to reference Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther 2018;13:1–11.PubMedPubMedCentralCrossRef Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther 2018;13:1–11.PubMedPubMedCentralCrossRef
29.
go back to reference Sharma BC, Sharma P, Lunia MK et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013;108:1458–1463.PubMedCrossRef Sharma BC, Sharma P, Lunia MK et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013;108:1458–1463.PubMedCrossRef
30.
go back to reference Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLoS ONE 2022;17:e0267647.PubMedPubMedCentralCrossRef Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLoS ONE 2022;17:e0267647.PubMedPubMedCentralCrossRef
31.
go back to reference Sanyal AJ, Heimanson Z, Israel R, et al. Prevention of overt hepatic encephalopathy recurrence with rifaximin alone versus rifaximin plus lactulose therapy: Impact on quality of life and caregiver burden in patients with cirrhosis. Presented at Hospital Medicine April 8–11, 2018, Orlando, FL, 2018. Sanyal AJ, Heimanson Z, Israel R, et al. Prevention of overt hepatic encephalopathy recurrence with rifaximin alone versus rifaximin plus lactulose therapy: Impact on quality of life and caregiver burden in patients with cirrhosis. Presented at Hospital Medicine April 8–11, 2018, Orlando, FL, 2018.
32.
go back to reference Bajaj JS, Heuman DM, Wade JB et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478–487.PubMedCrossRef Bajaj JS, Heuman DM, Wade JB et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478–487.PubMedCrossRef
34.
go back to reference Taylor MJ, McNicholas C, Nicolay C et al. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23:290–298.PubMedCrossRef Taylor MJ, McNicholas C, Nicolay C et al. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23:290–298.PubMedCrossRef
35.
go back to reference Kobsa A. Personalized hypermedia systems may be in conflict with privacy concerns of computer. Commun ACM 2002;45:64–67.CrossRef Kobsa A. Personalized hypermedia systems may be in conflict with privacy concerns of computer. Commun ACM 2002;45:64–67.CrossRef
36.
go back to reference Lampe C, Wohn DY, Vitak J et al. Student use of Facebook for organizing collaborative classroom activities. Int J Comput Support Collab Learn 2011;6:329–347.CrossRef Lampe C, Wohn DY, Vitak J et al. Student use of Facebook for organizing collaborative classroom activities. Int J Comput Support Collab Learn 2011;6:329–347.CrossRef
37.
38.
go back to reference Constantiou I, Kallinikos J. (2015). New games, new rules: big data and the changing context of strategy, LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library. Constantiou I, Kallinikos J. (2015). New games, new rules: big data and the changing context of strategy, LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library.
39.
go back to reference Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39:II46-54.PubMedCrossRef Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39:II46-54.PubMedCrossRef
40.
go back to reference Sittig DF, Wright A, Osheroff JA et al. Grand challenges in clinical decision support. J Biomed Inform. 2008;41:387–392.PubMedCrossRef Sittig DF, Wright A, Osheroff JA et al. Grand challenges in clinical decision support. J Biomed Inform. 2008;41:387–392.PubMedCrossRef
41.
go back to reference Fontaine P, Ross SE, Zink T, Schilling LM. Systematic review of health information exchange in primary care practices. J Am Board Fam Med 2010;23:655–670.PubMedCrossRef Fontaine P, Ross SE, Zink T, Schilling LM. Systematic review of health information exchange in primary care practices. J Am Board Fam Med 2010;23:655–670.PubMedCrossRef
42.
go back to reference Carroll C, Patterson M, Wood S et al. A conceptual framework for implementation fidelity. Implementation Sci 2007;2:40.CrossRef Carroll C, Patterson M, Wood S et al. A conceptual framework for implementation fidelity. Implementation Sci 2007;2:40.CrossRef
43.
go back to reference Prince M. Does active learning work? A review of the research. Journal of Engineering Education 2004;93:223–231.CrossRef Prince M. Does active learning work? A review of the research. Journal of Engineering Education 2004;93:223–231.CrossRef
44.
go back to reference Thistlethwaite JE, Davies D, Ekeocha S, et al. The effectiveness of case-based learning in health professional education. A BEME systematic review: BEME Guide No. 23. Med Teach. 2012;34:e421–44. Thistlethwaite JE, Davies D, Ekeocha S, et al. The effectiveness of case-based learning in health professional education. A BEME systematic review: BEME Guide No. 23. Med Teach. 2012;34:e421–44.
45.
go back to reference Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep). 2007:1–69. Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep). 2007:1–69.
46.
go back to reference Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700–5.PubMedCrossRef Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700–5.PubMedCrossRef
Metadata
Title
A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates
Authors
Patrick A. Twohig
Thoetchai Bee Peeraphatdit
Kaeli Samson
Makayla Schissel
Lynette Smith
Allison Ashford
Laura Freese
Timothy McCashland
Publication date
23-04-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08445-2
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.